
Prothea Technologies
A New Vision for Lung Cancer Treatment.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor | €0.0 | round | |
* | €12.0m | Series A | |
Total Funding | 000k |
Related Content
Prothea Technologies is a private medical technology company focused on revolutionizing lung cancer treatment. The company offers a groundbreaking solution that combines biopsy and treatment of lung cancer in a single hospital visit, significantly reducing the time to treat from weeks to minutes. This approach not only alleviates hospital pressures but also improves patient outcomes by providing faster and more efficient care.
Prothea Technologies primarily serves hospitals and healthcare providers, operating within the medical technology and healthcare markets. The business model is centered around providing advanced medical devices and solutions that streamline cancer treatment processes. Revenue is generated through the sale of these medical devices and associated services to healthcare institutions.
By integrating biopsy and treatment into one visit, Prothea Technologies addresses a critical need in the healthcare industry, offering a solution that enhances operational efficiency and patient care quality. The company's innovative approach positions it as a key player in the medical technology sector, with the potential to transform lung cancer treatment protocols globally.
Keywords: lung cancer, biopsy, treatment, medical technology, healthcare, hospital efficiency, patient outcomes, single visit, advanced devices, cancer care.